Helus Pharma to Present at Guggenheim Healthcare Innovation Conference

Helus Pharma's CEO will participate in a fireside chat at a major healthcare investment conference, offering investors a chance to hear about the company's progress in developing novel mental health treatments.

Houston Metrowire Staff
••Healthcare
Helus Pharma to Present at Guggenheim Healthcare Innovation Conference

Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform. A replay will be available on the Events & Presentations page of the company’s investor relations website.

The announcement matters because it gives investors and industry observers direct access to management at a critical time for Helus Pharma. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. The fireside chat provides a platform for Halstead to discuss these programs and the company’s strategy in addressing the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit www.helus.com. The full press release can be viewed at https://ibn.fm/LrRvm.

The conference participation is also significant because it comes as Helus Pharma continues to advance its research portfolio of investigational NSAs. The company’s presence at a prominent healthcare innovation event underscores its commitment to engaging with the investment community and raising awareness of its approach to mental health treatment. The webcast and replay ensure that a broader audience can access the discussion, which may include updates on clinical milestones and corporate developments. This kind of visibility can be particularly important for clinical-stage companies seeking to attract investment and build relationships with healthcare-focused investors.

InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, disseminated the announcement. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The announcement was disseminated on behalf of Helus Pharma and may include paid advertising.

Blockchain Registration

QR Code for Blockchain Registration